Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data

Degron Therapeutics, a US-China biotech firm, has successfully raised an additional $40 million in a Series A extension, bringing its total funding to $95 million for its innovative molecular glue degrader platform. This funding round highlights the growing interest and investment in biotech solutions, particularly in the CAR-T therapy space, as evidenced by Cabaletta's recent data release.